Under this year’s motto “partnering with patients: the cornerstone of cancer care and research”, oncology experts from around the world gathered at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, and virtually from 2nd–6th June 2023, to discuss the latest data in lung cancer with emphasis on practice-changing new studies, less toxic treatments, precision oncology and new ways to reduce collateral damage.
ASCO Solid Tumors 2022 - Kohei Shitara Kohei Shitara t ...
ASCO Solid Tumors 2022 - Anna Spreafico Anna Spreafico ...
ASCO Lung Cancer 2022 - John Varlotto John Varlotto su ...
ASCO Lung Cancer 2022 - Jessica Donington Jessica Doni ...
ASCO Solid Tumors 2022 - Ian Chau Ian Chau summarizes ...
ASCO Solid Tumors 2022 - Julien Edeline Julien Edeline ...
Hepatocellular carcinoma (HCC) affected approximately 905,000 new diagnosed cases worldwide in 2020 and showed a high mortality rate. Current first-line treatment for advanced HCC includes atezolizumab plus bevacizumab, as well as the tyrosine kinase inhibitors sorafenib and lenvatinib. Previously reported data of the KEYNOTE-224 single-arm, non-randomized, multicenter, open-label, phase II study (NCT02702414) in advanced HCC have shown that pembrolizumab monotherapy has a durable antitumor activity and a manageable safety profile in sorafenib-pretreated (cohort 1) and treatment-naive (cohort 2) patients.
n the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), the IMpower133 and CASPIAN trials have established the anti-PD-L1 antibodies atezolizumab and durvalumab, respectively, as standard-of-care treatment in addition to platinum-etoposide. However, PD-L1 inhibitors can only prolong overall survival by approximately 2 months and disease progression eventually develops in most cases, which still implies a significant unmet need for new therapies to improve long-term outcomes.
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, and it is the fourth most frequent cancer diagnosis.A current treatment option for RAS and BRAF wild-type (WT) metastatic colorectal cancer (mCRC) is the chemotherapy doublet (FOLFOX/FOLFIRI) with an anti-EGFR monoclonal antibody (cetuximab or panitumumab).
